A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Phase 2

• Conditions: PTCL
• Interventions: Drug: YY-20394 treatment

• Registration Number: NCT04705090
• Lead Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Brief Summary

A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-12
• Study First Submitted: 2021-01-08
• Study First Submitted QC: 2021-01-08
• Last Update Submitted: 2021-01-08
• Study First Posted: 2021-01-12
• Last Update Posted: 2021-01-12
• Study Start: 2021-04
• Primary Completion: 2022-12
• Study Completion: 2023-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Males and/or females over age 18.
• Histologically or cytologically confirmed diagnosis of relapsed or refractory peripheral T/NK cell lymphoma.
• Eastern Cooperative Oncology Group performance status of 0 to 1.
• Life expectancy of at least 3 months.
• At least one measurable lesion according to Lugano 2014.
• Adequate organ function.
• Had anti-tumor treatment within 2 weeks prior to the first dose of investigational product (including TKI, Chinese herbal anti-tumor treatment); within 4 weeks prior to the first dose of investigational product (including chemotherapy, radiotherapy, immunotherapy and major surgery); other targeted therapies with 5 half-life period prior to the first dose.
• Men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose.
• Volunteers did not participate in other clinical trials within 1 month prior to study entry.
• Provision of signed and dated, written informed consent prior to any study- specific evaluation.

Exclusion Criteria

• Previous treatment with any PI3K-delta inhibitors.
• Uncontrolled pleural effusion and ascites.
• The dosage of steroid hormone (prednisone equivalent) was greater than 20mg/day, and lasted for more than 14 days.
• Medical conditions in swallowing difficulty, malabsorption, or other chronic gastrointestinal disease that may hamper compliance and/ or absorption of the investigational agent.
• Drugs that may prolong the QT (such as anti-arrhythmic drugs) could not be interrupted during the study period.
• Evidence of central nervous system involvement of the malignancy, including invasion of brain parenchyma and meninges, or spinal cord compression.
• Have active viral, bacterial, fungal, or other infections that require systematic treatment (e.g., active tuberculosis), excluding nail bed fungal infections.
• Active infection with hepatitis B and C virus (volunteers with HBsAg or HBcAb positive but HBV-DNA negative, or HCV antibody positive but HCV-RNA negative can be enrolled).
• History of immune deficiency (acquired and congenital), or history of organ transplantation, or allogeneic bone marrow or hematopoietic stem cell transplantation; with active autoimmune disease or history of autoimmune disease (e.g., autoimmune enteritis and systemic lupus erythematosus).
• prior autologous hematopoietic stem cell transplantation within 90 days prior to the first dose of study drug.
• Presence of severe or uncontrolled cardiovascular disease.
• Medical history of active bleeding within 2 months prior to study entry, or currently achieved anticoagulant therapy, or susceptible to bleed by the judgement of investigator.
• Presence of concomitant diseases that are seriously endanger the safety of patient or affect the completion of the study by the investigator's judgment (e.g., uncontrolled hypertension, diabetes, thyroid diseases).
• Had received GCSF or blood transfusion treatment within 14 days prior to study entry.
• Female subjects of childbearing potential have a positive pregnancy test at the baseline.
• Medical history of other primary malignant tumors in the past 5 years except for the following: clinically cured cervical or breast carcinoma in situ, local basal cell or squamous cell carcinoma of the skin, thyroid tumor.
• Adverse events occurred during previous anticancer therapy have not been recovered to ≤1 (CTCAE 5.0) except toxicity with no significant risk determined by investigator such as alopecia.
• Live vaccine was administered within 30 days prior to the first dose of the investigational drug, or was scheduled to be administered during the study period.
• Judgment by the investigator that the volunteer should not participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
YY-20394 treatment	YY-20394 treatment	YY-20394 tablets, 20mg spec, 80mg QD, 28 days for each cycle.

Primary Outcome Measures

Name	Time	Method
ORR	up to 12 months	Objective Response Rate

Secondary Outcome Measures

Name	Time	Method
DOR	up to 12 months	Duration of response
PFS	up to 12 months	Progression free survival
DCR	up to 12 months	Disease control rate
TTR	up to 12 months	Time to response
Safety and Tolerability	up to 12 months	safety and tolerability of investigational Product assessed as the number of participants experiencing adverse events (AEs, CTCAE5.0) or abnormalities in vital signs, laboratory tests, or electrocardiograms.